Ionis Pharmaceuticals
| Formerly | Isis Pharmaceuticals, Inc. |
|---|---|
| Company type | Public |
| |
| Industry | Biotechnology |
| Founded | 1989 |
| Founder | Stanley T. Crooke |
| Headquarters | Carlsbad, California, U.S. |
Key people | Brett P. Monia (CEO) Elizabeth L. Hougen (CFO) Joseph Loscalzo (chairman of the board) |
| Products | nusinersen, inotersen, volanesorsen, olezarsen, eplontersen, tofersen |
| Revenue | US$705 million (2024) |
| US$−270 million (2022) | |
| Total assets | US$3 billion (2024) |
| Total equity | US$588 million (2024) |
Number of employees | 1,069 (2024) |
| Website | ionispharma |
| Footnotes / references | |
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza (Nusinersen), Tegsedi (Inotersen), and Waylivra (Volanesorsen), and has four drugs in pivotal studies: tominersen for Huntington's disease (together with Roche), tofersen for SOD1-ALS, AKCEA-APO(a)-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.
The company was named Isis Pharmaceuticals until December 2015.